Abstract: An instrument for reading a lateral flow assay device by detecting color changes based on human perception includes an optics module having a camera, a signal processor, a storage memory and a comparator circuit. The storage memory has stored therein a dataset of sample readings of reference assay devices similar in structure and function to that of the lateral flow assay device. The sample readings are based on human visual perceptions of colorimetric changes in the detection zones of the reference assay devices. The comparator circuit compares the measured colorimetric data relating to the assay device read by the instrument with the stored database of sample readings based on human visual perceptions of the colorimetric changes of the reference assay devices, and generates a comparison signal which is provided to the signal processor. The signal processor generates a determination signal indicative of the presence, absence or quantity of an analyte.

Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound (E), wherein R1 is described herein. Compound (E) can be useful in synthesizing compound (A1), or a salt or solvate thereof, and compound (A2), or a salt of solvate thereof.

Abstract: An instrument for reading a lateral flow assay device by detecting color changes based on human perception includes an optics module having a camera, a signal processor, a storage memory and a comparator circuit. The storage memory has stored therein a dataset of sample readings of reference assay devices similar in structure and function to that of the lateral flow assay device. The sample readings are based on human visual perceptions of colorimetric changes in the detection zones of the reference assay devices. The comparator circuit compares the measured colorimetric data relating to the assay device read by the instrument with the stored database of sample readings based on human visual perceptions of the colorimetric changes of the reference assay devices, and generates a comparison signal which is provided to the signal processor. The signal processor generates a determination signal indicative of the presence, absence or quantity of an analyte.

Abstract: An instrument for reading a lateral flow assay device by detecting color changes based on human perception includes an optics module having a camera, a signal processor, a storage memory and a comparator circuit. The storage memory has stored therein a dataset of sample readings of reference assay devices similar in structure and function to that of the lateral flow assay device. The sample readings are based on human visual perceptions of colorimetric changes in the detection zones of the reference assay devices. The comparator circuit compares the measured colorimetric data relating to the assay device read by the instrument with the stored database of sample readings based on human visual perceptions of the colorimetric changes of the reference assay devices, and generates a comparison signal which is provided to the signal processor. The signal processor generates a determination signal indicative of the presence, absence or quantity of an analyte.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: An instrument for reading a lateral flow assay device by detecting color changes based on human perception includes an optics module having a camera, a signal processor, a storage memory and a comparator circuit. The storage memory has stored therein a dataset of sample readings of reference assay devices similar in structure and function to that of the lateral flow assay device. The sample readings are based on human visual perceptions of colorimetric changes in the detection zones of the reference assay devices. The comparator circuit compares the measured colorimetric data relating to the assay device read by the instrument with the stored database of sample readings based on human visual perceptions of the colorimetric changes of the reference assay devices, and generates a comparison signal which is provided to the signal processor. The signal processor generates a determination signal indicative of the presence, absence or quantity of an analyte.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.